ISS suggest Enhabit shareholders elect three AREX Capital nominees to board
By Svea Herbst-Bayliss
July 11 (Reuters) -Institutional Shareholder Services (ISS) on Thursday said Enhabit EHAB.N shareholders should elect three AREX Capital Management director candidates to the nine member board, arguing the company needs more expertise in home health, hospice and public company financial reporting.
The prominent proxy advisory firm, whose recommendations often guide shareholder votes on proposed mergers and who serves on a board, said AREX made a convincing case that new directors are needed. But the hedge fund did not persuade ISS that a majority of the two-year-old company's directors should be ousted, the report reviewed by Reuters said.
AREX is asking investors to replace seven directors to help reverse poor financial performance. It has also been pushing the home health and hospice provider to put itself up for sale.
Investors will vote on July 25 unless the two sides reach an agreement before the meeting date.
"The company's significant underperformance, both from a TSR (total shareholder return) and operational standpoint, indicate that a degree of change is needed at the board level," ISS wrote. Enhabit's stock price has tumbled nearly 60% since it was spun off of post-acute healthcare services provider Encompass Health EHC.N in July 2022.
ISS recommended votes for AREX candidates Gregory Sheff, who has home health operations experience, Anna-Gene O'Neal, who has hospice experience, and Mark Ohlendorf, who has public company chief financial officer experience.
AREX, which owns a 4.9% stake in Enhabit, is backing Enhabit CEO Barbara Jacobsmeyer and director Barry Schochet for reelection. Schochet joined the board last year when the company reached an agreement with investors Cruiser Capital and Harbour Point Capital Management in March 2023.
AREX told Enhabit last year that it wanted the company to commit to immediately start a strategic review before the end of 2023. Enhabit in May said it decided to continue as an independent, public company after having evaluated a range of strategic options.
A company representative was not immediately available for comment on the ISS recommendation and AREX declined to comment.
Reporting by Svea Herbst-Bayliss; Editing by Christian Schmollinger
Related Assets
Latest News
Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.
All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.
Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.
